

VOLUMEN 51

NUMERUS suppl 2

LIBRI ONCOLOGICI

CROATIAN JOURNAL OF ONCOLOGY

Zagreb, 2023

CROATIAN JOURNAL OF ONCOLOGY
LIBRI ONCOLOGICI

Publisher

Sestre milosrdnice University Hospital Center
University Hospital for Tumors, Zagreb, Croatia

Editor-in-Chief

Ivan Milas

Editors

Lidija Beketić-Orešković, Antonio Juretić, Božena Šarčević

Associate Editors

Iva Kirac – Experimental Research
Mladen Stanec – Surgical Oncology
Robert Šeparović – Medical Oncology
Martina Mikulandra – Radiation Oncology

Technical Editor

Anica Vrdoljak

Editorial Board

Gordana Brozović, Željko Herceg, Ljiljana Mayer, Aleksandar Milenović, Melita Perić Balja, Mario Puljiz, Snježana Ramić, Vesna Ramljak, Andrej Roth, Sanda Šitić, Danko Velimir Vrdoljak, Tiha Vučemilo

Editorial Council

M. Ćorić (Zagreb, Croatia), T. Čufer (Ljubljana, Slovenia), N. Đaković (Zagreb, Croatia), M. Gamulin (Zagreb, Croatia), D. Kalafatić (Zagreb, Croatia), S. Kaštelan (Zagreb, Croatia), Ž. Kaštelan (Zagreb, Croatia), M. Klarica (Zagreb, Croatia), D. Krleža (Dublin, Ireland), J. Koeva-Balabanova (Sofia, Bulgaria), D. La Forgia (Bari, Italy), A. Lancia (Pavia, Italy), D. Marčinko (Zagreb, Croatia), A. Mrkonjić (Malmö, Sweden), S. Orešković (Zagreb, Croatia), P. Ozretić (Zagreb, Croatia), S.Ž. Pavletić (Bethesda, USA), I. Tomaš (Osijek, Croatia), D. Vagić (Zagreb, Croatia), E. Vrdoljak (Split, Croatia), Ž. Vujašković (Baltimore, USA)

This journal is indexed or abstracted by:

**SCOPUS, DOAJ, HRČAK, Scilit Basel, CrossReff, Index Copernicus, Google Scholar,
ResearchGate, JournalsPedia**

Editorial Office:

LIBRI ONCOLOGICI, Ilica 197, 10 000 Zagreb, Croatia

Phone (385 1) 37 83 522

Web site: <http://hrcak.srce.hr/libri-oncologici>

e-mail: libri.oncologici@kbcsm.hr

The journal is published three times a year. Orders can be placed directly to the Editorial Office.

Price per copy 10 €. Annual subscription rates in Croatia: 45 € + VAT for institutions, 21 € + VAT for individuals and 10 € + VAT for students, to be remitted with Hrvatska narodna banka, account HR12 1001 0051 8630 0016 0 Ref.No.HR65 7129-051-26395 (for LIBRI ONCOLOGICI).

Annual subscription abroad - equivalent of US\$ 50 to be paid into the foreign currency account with Hrvatska narodna banka, IBAN: HR12 1001 0051 8630 0016 0 (Ref.No.HR65 7129-051-26395), BIC code: NBHRHR2XXXX (for LIBRI ONCOLOGICI)

Cover Design: Osman Berberović

Typesetting and printed by DENONA d.o.o., Zagreb

Publishing of Libri Oncologici is supported by the Ministry of Science and Education of the Republic Croatia

4th REGIONAL CONGRESS OF MEDICAL ONCOLOGY

IV. REGIONALNI KONGRES INTERNISTIČNE ONKOLOGIJE /REKONIO/

07. 09. - 09. 09. 2023.

Ljubljana

Supplement editors:

Ana Tečić Vuger and Tanja Mesti



Ljubljana, Slovenia
September, 2023

ORGANISERS:

Slovenian Medical Association - Section for Medical Oncology
Regional Cooperative Oncology Group, REKOG
Institute of Oncology Ljubljana

Expert Committee:

Janja Ocvirk (president)
Tanja Mesti
Simona Borštnar
Erika Matos
Stjepko Pleština
Borislav Belev
Davorin Radosavljević
Anes Pašič

Organizing Committee:

Janja Ocvirk (president)
Tanja Mesti
Simona Borštnar
Erika Matos

Poster Awards Committee:

Tanja Mesti (president)
Borislav Belev
Davorin Radosavljević
Lazar Popović
Erika Matos

PROGRAM

4th REGIONAL CONGRESS OF MEDICAL ONCOLOGY
| 07. - 09. September 2023 | LJUBLJANA

07th September 2023

09.30-11.00 REGISTRATION

11.00-13.30 *Genitourinary cancers: Moderated by Seruga, Belev*

11.00-11.20 **How far have we come with immuno-oncology in GU cancers?** Gnjidic

11.20-11.40 **Beyond immunotherapy: new targets and new drugs in GU cancers:** Belev

11.40-12.00 **Management of oligometastatic and oligo-progressive disease in GU:** Milasevic

12.00-12.20 **Onco-nephrology: current concepts and future perspectives:** Milanez

12.20-12.40 **What does the future bring in the systemic treatment of GU cancers?** Seruga

12.40-13.30 *Integrating supportive & palliative care & geriatrics with oncology - clinical cases:
Round table*

Moderated by Ebert

Panellists: Ebert, Bosnjak, Zist, Cale

- Supportive care
 - Palliative care
 - Geriatric oncology
-

13.30-14.30 **Lunch break**

14.30-17.30 *Clinical controversies in the breast cancer*

14.30-16.00 **Early breast cancer** (Slovenian medical oncologists will present actual cases):
Moderated by Borstnar

Panellists: Silovski, Popovic, Lekic, Susnjar, Ribnikar, Caks, Dobovisek, Pernek

- **How to decide to omit chemotherapy in early HR+/Her2- BC: gene signatures and other biomarkers:** Borštinar
 - **Duration of endocrine therapy:** Ribnikar
 - **Optimal treatment in early HER2 + BC:** Caks
 - **Post Neoadjuvant therapy in TNBC:** Dobovisek
 - **Adjuvant systemic therapy for patients with germline BRCA1/2 mutations:** Pernek
-

16.00-16.20 **Break**

16.20-18.00 *Advanced breast cancer* (Slovenian medical oncologists will present actual cases):
Moderated by Borstnar

Panellists: Beslija, Dedic- Plavetic, Stamatovic, Bozovic- Spasojevic, Matos,
Ovcaricek, Kovac, Demsar, Grašic Kuhar, Snoj Sarvari

- **The treatment beyond CDK4/6 in ABC:** Matos
- **Management of patients with metastases in CNS:** Ovcaricek
- **HER2-low ABC:** Kovac
- **Oligometastatic disease:** Demsar
- **Optimal management of a patient with ABC in a visceral crisis:** Grasic Kuhar
- **Optimal management of an older frail patient with ABC:** Snoj Sarvari

08th September 2023

09.00-09.30 *Head and neck cancers:* Moderated by Kuhar Grasic

Discussion on experience with chemo-(immuno)therapy vs. mono-chemotherapy in relapsed/metastatic head and neck cancer Bisof, Kuhar Grasic

09.30-10.10 *Round table – molecular markers in systemic therapy:* Moderated by Mesti

Panellists: Dedic-Plavetic, Mesti, Devjak
Presentation of clinical cases: Leskovsek

10.10-10.30 **Break**

10.30-13.30 *Lung cancers:* Moderated by Unk, Radosavljevic

Resectable NSCLC

10.30-10.50 **Adjuvant treatment in NSCLC – to whom and when?** Trivanovic

10.50-11.10 **How to optimise perioperative treatment?** Turnsek

11.10-11.30 **The value of “early” end-points (MPR, pCR) in neoadjuvant trials:** Devjak

11.30-12.00 **Discussion**

Metastatic NSCLC

12.00-12.20 **How far have we come with check-point inhibitors in metastatic NSCLC?** Unk

12.20-12.40 **How to manage patients after CPI resistance?** Plestina

12.40-13.00 **Druggable genomic alterations and available drugs in our region** Radosavljevic

13.00-13.30 **Discussion**

13.30-14.30 **Lunch break**

14.30-16.40 *Gastrointestinal cancers: Moderated by Plestina, Ocvirk*

Upper GI cancers

14.30-14.50 **The future of the systemic treatment of the upper GIT cancers:** Ocvirk

Pancreatic and hepatobiliary cancers

14.50-15.10 **Pancreatic cancer - The future of the systemic treatment:** Nikolic

15.10-15.30 **Hepatobiliary cancers – what a step forward:** Plestina

Colorectal cancer

15.30-15.50 **The role of Gender differences in diagnosis and treatment of colorectal cancer:** Pasic

15.50-16.40 **Systemic treatment of the GIT cancers – to infinity and beyond:** Moderated by Belev

Panellists: Belev, Pasic, Rebersek, Mijalkovic, Nikolic

Presentation of clinical cases: Erman

16.40-17.00 **Break**

17.00-17.30 *Poster session*

17.30-18.30 *Cooperation in the region*

09th September 2023

08.30-10.10 *Rare cancers: Moderated by Mesti*

08.30-08.50 **Ocular melanoma:** Simetic

08.50-09.10 **Cancer of unknown origin: Does primary origin still matter in the era of molecular profiling?** Matos

09.10-09.30 **GIST:** Belev

09.30-09.50 **Tailoring systemic therapy for medullary thyroid cancer:** Grasic Kuhar

09.50-10.10 **The clinical importance of molecular characteristics in brain cancers:** Mesti

10.10-10.50 *Gynaecological cancers: Moderated by Ravnik*

10.10-10.30 **The importance of BRCA/HRD status in tailoring maintenance treatment in 1st line ovarian cancer:** Stamatovic

10.30-10.50 **Immunotherapy in gynaecologic oncology – a new standard in metastatic endometrial and cervical cancer:** Ravnik

10.50-11.20 **Break**

11.20-13.00 **Skin cancers:** Moderated by Kandolf Sekulovic, Hribernik

Non-melanoma skin cancers

11.20-11.40 **Neoadjuvant/adjuvant immunotherapy in non-melanoma skin cancers:** Ocvirk

Melanoma

11.40-12.00 **Neoadjuvant and/or adjuvant immunotherapy in malignant melanoma
– the best approach:** Jalovic Suljevic

12.00-12.20 **Immune-related adverse events – the true meaning for skin cancer patients:** Hribernik

12.20-13.00 **Systemic treatment of skin cancer and beyond:** Moderated by Kandolf Sekulovic
Panellists: Ocvirk, Herceg, Kandolf Sekulovic, Jalovic Suljevic,
Presentation of clinical cases: Sever

13.00-13.15 **Closing remarks**
Ocvirk

Contents

ORAL PRESENTATIONS

Milena Gnjudić	
S1 – How far we have come with immuno-oncology in GU cancers?	3
Tomaž Milanez, Janja Ocvirk, Miha Arnol, Edgar A. Jaimes	
S2 – Onco-nephrology: The current concept and future perspectives	5
Simona Borštnar	
S3 – How to decide to omit chemotherapy in early HR+/HER2- breast cancer	6
Domen Ribnikar	
S4 – Tailoring extended adjuvant endocrine therapy in early-stage HR + breast cancer	7
Marina Čakš	
S5 – Optimal treatment in early HER2 positive BC	8
Luka Dobovišek	
S6 – Post-neoadjuvant therapy in triple-negative breast cancer.	10
Matej Pernek	
S7 – Adjuvant systemic therapy for patients with germline BRCA1/2 mutations	11
Erika Matos, Kaja Cankar, Katja Dejanović, Neža Režun	
S8 – Treatment beyond CDK4/6 inhibitor in HR+ HER2- ABC	12
Tanja Ovčariček	
S9 – Management of breast cancer patients with brain metastases.	13
Anja Kovač	
S10 – HER2-low breast cancer – definition, dilemmas and new systemic therapy options.	15
Ana Demšar	
S11 – Oligometastatic breast cancer	16
Cvetka Grašič Kuhar	
S12 – Optimal management of a patient with advanced breast cancer in a visceral crisis	17
Vesna Bišof, Majana Soče, Spomenka Mikuš, Sanja Vušković	
S13 – Discussion on experience with chemo(immuno)therapy vs. mono-immunotherapy in relapsed/metastatic head and neck cancer	18

Natalija Dedić Plavetić, Tanja Mesti, Rok Devjak	
S14 – Molecular markers in systemic therapy	19
Rok Devjak	
S15 – The value of <i>early</i> end-points (MPR, pCR) in neoadjuvant trials	20
Sanja Pleština	
S16 – How to manage patients after CPI resistance?	20
Davorin Radosavljević	
S17 – Druggable genomic alterations in metastatic NSCLC and available drugs in our region	21
Janja Ocvirk	
S18 – The future of the systemic treatment of the upper GIT cancers	22
Erika Matos, Kaja Cankar, Neža Režun, Katja Dejanović	
S19 – Cancer of unknown primary: does primary still matter in the era of molecular profiling?	23
Cvetka Grašič Kuhar	
S20 – Tailoring systemic therapy for medullary thyroid cancer.	25
Tanja Mesti	
S21 – The clinical importance of molecular characteristics in brain cancers	26
Maja Ravnik	
S22 – Immunotherapy in gynecologic oncology – new standard in metastatic endometrial and cervical cancer	28
Janja Ocvirk	
S23 – Neoadjuvant/adjuvant immunotherapy in non-melanoma skin cancers	29
Amina Jalovčić-Suljević	
S24 – Neoadjuvant and/or adjuvant immunotherapy in malignant melanoma – the best approach	30
Nežka Hribernik	
S25 – Immune-related adverse events: The true meaning for skin cancer patients.	31
Anes Pašić, Elma Kapisazović, Emir Sokolović, Emina Borovac-Gurda, Una Stojanović	
S26 – Sex and gender differences in colon cancer	31
Maja Ebert Moltara, Snežana Bošnjak, Sanda Čale, Andrej Žist	
S27 – Integrating supportive & palliative care & geriatrics with oncology – clinical cases	32
Nataša Snoj Šarvari	
S28 – Optimal management of an older frail patient with ABC.	33
Nikola Milašević	
S29 – Management of oligometastatic and oligo-progressive disease in GU	34
Ivan Nikolić	
S30 – Pancreatic cancer-The future of the systemic treatment	35

Ljiljana Stamatović	
S31 – The importance of BRCA/HRD status in tailoring maintenance treatment in 1st line ovarian cancer.	36
Luka Simetić	
S32 – Ocular melanoma	37
Borislav Belev	
S33 – Beyond immunotherapy: new targets and new drugs in GU cancers	38
Dragan Trivanović	
S34 – Adjuvant treatment in NSCLC – to whom and when?.	39
Borislav Belev	
S35 – Gastrointestinal stromal tumor (GIST)	40
Stjepko Pleština	
S36 – Hepatobiliary cancers – What a step forward!	41

POSTER PRESENTATIONS

Gordan Adžić, Hana Lučev, Domina Kekez, Irma Goršić, Nikša Librenjak, Juraj Prejac, Stjepko Pleština	
P1 – Perioperative FLOT chemotherapy in real-world setting – single center experience.	45
Miće Božić, Tanja Mesti, Cvetka Grašič Kuhar, Janja Ocvirk	
P2 – Biomarkers of treatment outcome in patients with metastatic melanoma treated with first-line immune checkpoint inhibitors – a single-institution, retrospective analysis	46
Šime Bušelić, Marija Gamulin, Milena Gnjidić, Zrna Antunac Golubić, Ana Koši Kunac	
P3 – Avelumab as a maintenance therapy in advanced urothelial carcinoma: one-year experience at University Hospital Centre Zagreb	47
Katarina Čular, Ana Magdalena Glas, Dora Gudelj, Kristina Kanceljak, Laura Barta, Marija Križić, Marina Popović, Stela Bulimbašić, Natalija Dedić Plavetić, Tajana Silovski	
P4 – Effectiveness of CDK 4/6 inhibitors in the first-line treatment of patients presenting with visceral crisis: real-world data	48
Blaž Tomič, Maša Sever, Janja Ocvirk, Tanja Mesti	
P5 – Results of systemic treatment for squamous cell skin cancer at the Institute of Oncology Ljubljana	49
Fedja Djordjević, Neda Nikolić, Katarina Ljujić, Dimitrije Kolovič, Nemanja Stanić, Davorin Radosavljević, Marija Ristić, Jelena Spasić	
P6 – Adoption of total neoadjuvant therapy (TNT) for locally advanced rectal cancer: single centre experience from the Institute for Oncology and Radiology of Serbia (IORS)	50

Renata Kelemenčić-Dražin, Anuška Budisavljević, Natalija Dedić Plavetić, Tajana Silovski, Stjepko Pleština	
P7 – Next-generation sequencing (NGS) in routine oncology practice in Croatia	51
Branko Dujović, Aleksandar Popović, Bojana Cikota-Aleksić, Ivana Jocić, Lidija Kandolf Sekulović	
P8 – Inflammatory biomarkers as a predictive parameter for the first-line anti-PD1 immunotherapy in metastatic melanoma: Multicentre retrospective study	52
Ana Erman, Marija Ignjatović, Katja Leskovšek, Simona Miceska, Urša Lampreht Tratar, Maša Bošnjak, Veronika Kloboves Prevodnik, Maja Čemažar, Lidija Kandolf Sekulović, Gorazd Avguštin, Janja Ocvirk, Tanja Mesti	
P9 – The prognostic and predictive value of human gastrointestinal microbiome and exosomal mRNA expression of PD-L1 and IFNγ for immune checkpoint inhibitors response in metastatic melanoma patients: protocol trial	53
Dora Gudelj, Katarina Čular, Ana Kelečić, Iva Kukal, Lea Toula, Marija Križić, Marina Popović, Natalija Dedić Plavetić, Gordana Ivanac, Tajana Silovski	
P10 – Combined influence of PD-L1 expression and HER2-low status on clinical outcomes of neoadjuvant chemotherapy in early triple negative breast cancer (TNBC)	54
Iva Ivanković, Kristina Kanceljak, Eva Paponja, Ivana Rako, Tamara Žigman, Marina Popović, Tajana Silovski, Natalija Dedić Plavetić	
P11 – Breakdown of biological subtypes in breast cancer patients with germline BRCA 1/2 and beyond-BRCA mutations treated with neoadjuvant chemotherapy	55
Koviljka Ivić, Mila Purić, Dušan Ristić, Branka Živković, Nenad Milanović	
P12 – Anticoagulant therapy in patients with malignancies/risk assessment during chemo-radiotherapy treatment	56
Kristina Kanceljak, Katarina Čular, Dora Gudelj, Ana Kelečić, Marko Lovrić, Marija Križić, Marina Popović, Natalija Dedić Plavetić, Maja Sirotković Skerlev, Tajana Silovski	
P13 – Impact of HER2-low status on effectiveness of first line treatment with CDK4/6 inhibitors in patients with HR-positive, HER2-negative metastatic breast cancer (mBC): single institution experience.	57
Andrijana Kojić, Branka Živković, Dušan Ristić, Mila Purić, Jovana Mijucić, Nenad Milanović	
P14 – Diffuse large B-cell lymphoma: 5 years single institution experience (Institute for Oncology and Radiology of Serbia).	58
Katja Leskovšek, Ana Erman, Tanja Mesti, Janja Ocvirk	
P15 – Outcomes of ramucirumab combined with paclitaxel among Slovenian patients with metastatic gastric/gastroesophageal junction adenocarcinoma: a retrospective study.	59

Katarina Ljujić, Fedja Djordjević, Marija Ristić, Neda Nikolić, Dimitrije Kolovič, Davorin Radosavljević, Jelena Spasić	
P16 – Is there a difference in the mechanisms of development of skin toxicity between EGFR TKIs: A case presentation of severe skin adverse event during treatment with afitinib	60
Nikolina Lonjak, Josip Mavrek, Marko Lovrić, Josipa Meštrović, Karla Mirčevski, Petar Matošević, Stjepko Pleština, Tajana Silovski, Sanda Bubanović, Hrvoje Silovski	
P17 – Clinical outcomes of neoadjuvant treatment in locally advanced rectal cancer: multi-institutional experience	61
Marko Lovrić, Nikolina Lonjak, Josip Mavrek, Sanda Bubanović, Natalija Dedić Plavetić, Tajana Silovski, Branko Bogdanić, Majana Soče, Igor Petrović, Hrvoje Silovski	
P18 – Effect of body mass index (BMI) on pathological response after neoadjuvant therapy in locally advanced rectal cancer.	62
Maša Auprih, Barbara Gazić, Primož Drev, Simona Borštnar	
P19 – The frequency of HER2-low breast cancer among patients diagnosed at the Institute of Oncology Ljubljana from 2011 to 2021	63
Maša Auprih, Gorana Gašljević, Simona Borštnar	
P20 – Biomarker guided first-line treatment of metastatic triple negative breast cancer	64
Maša Auprih, Kaja Cankar, Simona Borštnar	
P21 – Pembrolizumab in neoadjuvant setting for early TNBC – real world data	66
Maša Auprih, Simona Borštnar	
P22 – Real-world outcomes with sacituzumab govitecan in a single-centre study	67
Maša Auprih, Gorana Gašljević, Eva Šetina, Anja Žižek, Simona Borštnar	
P23 – Metaplastic breast cancer: a single center retrospective study	69
Erika Matos, Kaja Cankar, Neža Režun, Katja Dejanović, Maša Auprih, Tanja Ovčariček	
P24 – Efficacy and safety of abemaciclib in the treatment of HR+ HER2- advanced breast cancer: real world data	70
Sofija Pantelić, Ana Cvetković, Nenad Milanović, Mila Purić, Nikola Lemajić	
P25 – Thrombotic complications associated with DA-EPOCH-R therapy for non-Hodgkin’s lymphoma	71
Eva Paponja, Kristina Kanceljak, Iva Ivanković, Ivana Rako, Tamara Žigman, Marina Popović, Tajana Silovski, Natalija Dedić Plavetić	
P26 – Neoadjuvant treatment outcomes in patients with germline BRCA 1/2 and beyond-BRCA mutations: examining pathological complete response rates	72
Ela Markočič Rojc, Janja Ocvirk	
P27 – Treatment of pancreatic ductal adenocarcinoma with liposomal irinotecan with 5-fluorouracil and leucovorin in Institute of Oncology Ljubljana	73

Josip Mavrek, Nikolina Lonjak, Marko Lovrić, Sanda Bubanović, Tonći Vodopić, Branko Bogdanić, Petar Matošević, Ivan Romić, Igor Petrović, Hrvoje Silovski P28 – Comparision between estimated T/N stage by MRI and pathological findings in patients with locally advanced rectal cancer after neoadjuvant therapy: multi-institutional experience	74
Jovana Mijucić, Dušan Ristić, Nenad Milanović, Jelena Sopta P29 – Synovial sarcoma – where are we?	75
Marija Milosavljević, Nemanja Stanić, Kristina Juskić, Tamara Ursulović, Suzana Matković P30 – Body mass index (BMI) and adult comorbidity evaluation 27 (ACE-27) as a prognostic factor of overall survival (OS) in locally advanced head and neck (H/N) cancer patients	76
Marijana Milović-Kovačević, Lidija Pavlović, Milana Matović, Simonida Bobić, Slobodan Kutić, Ljiljana Stamatović P31 – Olaparib as a first-line maintenance treatment for BRCA-positive ovarian cancer patients: single-institution experience	76
Tamara Ursulović, Nemanja Stanić, Marija Milosavljević, Dimitrije Đurđević, Vukac Vujanac, Nataša Jovanović Korda P32 – New therapeutical approach in treatment of nasopharyngeal cancer: sequentional chemotherapy Epirubicin-Cisplatin combined with radiotherapy, a eighteen years of follow up.	77
Alenksandra Sokolova, Aljoša Andlovic, Mojca Unk, Nina Turnšek P33 – Neurological immune related adverse events associated with immune checkpoint inhibitors – real world data from single cancer center	78
Emir Sokolović, Una Stojanović, Amil Družić, Elma Kapisazović, Emina Borovac-Gurda, Mujo Kadrić, Emina Bičakčić-Filipović, Suada Kuskunović-Vlahovljak, Alma Bašić Smajić, Anes Pašić P34 – FOLFIRINOX in initially metastatic pancreatic cancer: a single-center retrospective study	79
Cvetka Grašič Kuhar P35 – Slovenian experiences of vandetanib efficacy and toxicity in advanced/metastatic medullary thyroid cancer.	80
AUTHOR INDEX	81